It's Zehrid Osmani, Head of Long-Term Unconstrained. Today we are going to talk about Masimo.
Masimo is the typical type of companies that we invest in. It is a leader in the non-invasive patient monitoring hospital devices and technologies.
It operates in a supportive industry structure, with high barriers to entry and limited competitive pressures.
These characteristics gives it superior pricing power - as a rule, we like companies with good pricing power, in a world where there is strong underlying deflationary trends.
The company also has low disruption risk, due to its productive and targeted R&D efforts, enabling it to sustain its leadership position.
It has attractive growth prospects, driven by supportive long term structural trends, related to ageing population, improved healthcare infrastructure, and future of technology related to intelligent patient monitoring.
It has a good quality management and supportive ESG and, importantly, a sustainable business model. It is a great opportunity to gain exposure to three important long-term themes that we have identified as part of our thematics framework, which are: Aging Population, Bespoke Healthcare and Robotics & Automation. Those are part of our three megatrends which are Demographic Change, Future of Technology and Resource Scarcity.
LONG-TERM UNCONSTRAINED INSIDE STORIES
The inside story on the leading companies in our global portfolio and why they offer sustainable, long-term growth potential.
This information is issued and approved by Martin Currie Investment Management Limited (‘MCIM’), authorised and regulated by the Financial Conduct Authority. It does not constitute investment advice. Market and currency movements may cause the capital value of shares, and the income from them, to fall as well as rise and you may get back less than you invested.
The information contained in this document has been compiled with considerable care to ensure its accuracy. However, no representation or warranty, express or implied, is made to its accuracy or completeness. Martin Currie has procured any research or analysis contained in this document for its own use. It is provided to you only incidentally and any opinions expressed are subject to change without notice.
This document may not be distributed to third parties. It is confidential and intended only for the recipient. The recipient may not photocopy, transmit or otherwise share this video, or any part of it, with any other person without the express written permission of Martin Currie Investment Management Limited.
The document does not form the basis of, nor should it be relied upon in connection with, any subsequent contract or agreement. It does not constitute, and may not be used for the purpose of, an offer or invitation to subscribe for or otherwise acquire shares in any of the products mentioned.
Past performance is not a guide to future returns.
The views expressed are opinions of the portfolio managers as of the date of this document and are subject to change based on market and other conditions and may differ from other portfolio managers or of the firm as a whole. These opinions are not intended to be a forecast of future events, research, a guarantee of future results or investment advice.
Please note the information within this report has been produced internally using unaudited data and has not been independently verified. Whilst every effort has been made to ensure its accuracy, no guarantee can be given.
The information provided should not be considered a recommendation to purchase or sell any particular strategy / fund / security. It should not be assumed that any of the securities discussed here were or will prove to be profitable.
For institutional investors in the USA:
The information contained within this presentation is for Institutional Investors only who meet the definition of Accredited Investor as defined in Rule 501 of the United States Securities Act of 1933, as amended (‘The 1933 Act’) and the definition of Qualified Purchasers as defined in section 2 (a) (51) (A) of the United States Investment Company Act of 1940, as amended (‘the 1940 Act’). It is not for intended for use by members of the general public.
For wholesale investors in Australia:
This material is provided on the basis that you are a wholesale client within the definition of ASIC Class Order 03/1099. MCIM is authorised and regulated by the FCA under UK laws, which differ from Australian laws.
Martin Currie Investment Management Limited, registered in Scotland (no SC066107) Martin Currie Inc, incorporated in New York and having a UK branch registered in Scotland (no SF000300), Saltire Court, 20 Castle Terrace, Edinburgh EH1 2ES Tel: (44) 131 229 5252 Fax: (44) 131 222 2532 www.martincurrie.com. Both companies are authorised and regulated by the Financial Conduct Authority. Martin Currie Inc, 280 Park Avenue, New York, NY 10017 is also registered with the Securities Exchange Commission. Please note that calls to the above number and any other communications may be recorded.